UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,451 Shares of Encompass Health Corporation $EHC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in shares of Encompass Health Corporation (NYSE:EHC) by 2.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 289,353 shares of the company’s stock after selling 7,451 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Encompass Health were worth $29,248,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in EHC. BlackRock Inc. bought a new stake in Encompass Health in the second quarter worth $1,059,762,000. Price T Rowe Associates Inc. MD grew its stake in shares of Encompass Health by 24.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,805,413 shares of the company’s stock valued at $510,047,000 after buying an additional 948,202 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Encompass Health by 3,059,159.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock worth $402,640,000 after buying an additional 3,793,358 shares during the period. Wellington Management Group LLP lifted its stake in shares of Encompass Health by 21.7% in the 4th quarter. Wellington Management Group LLP now owns 3,384,877 shares of the company’s stock valued at $359,271,000 after acquiring an additional 603,472 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in Encompass Health by 27.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,722,887 shares of the company’s stock valued at $289,008,000 after acquiring an additional 581,812 shares during the period. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Mark J. Tarr sold 173,148 shares of Encompass Health stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $125.47, for a total transaction of $21,724,879.56. Following the completion of the transaction, the chief executive officer directly owned 267,814 shares of the company’s stock, valued at $33,602,622.58. This trade represents a 39.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP John Darby sold 4,858 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $121.09, for a total transaction of $588,255.22. Following the sale, the executive vice president directly owned 75,041 shares in the company, valued at $9,086,714.69. The trade was a 6.08% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 186,912 shares of company stock worth $23,434,845. Company insiders own 1.80% of the company’s stock.

Encompass Health Stock Up 1.3%

Shares of Encompass Health stock opened at $122.79 on Friday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.76. Encompass Health Corporation has a 12-month low of $92.77 and a 12-month high of $127.99. The company has a market cap of $12.11 billion, a P/E ratio of 20.00, a PEG ratio of 2.45 and a beta of 0.75. The company’s fifty day simple moving average is $114.92 and its two-hundred day simple moving average is $107.48.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.07. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. Encompass Health’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.40 earnings per share. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. Research analysts anticipate that Encompass Health Corporation will post 6.08 EPS for the current year.

Encompass Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, October 1st will be given a dividend of $0.21 per share. This is an increase from Encompass Health’s previous quarterly dividend of $0.19. This represents a $0.84 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Thursday, October 1st. Encompass Health’s payout ratio is 12.38%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on EHC shares. TD Cowen raised their price target on Encompass Health from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. UBS Group increased their price objective on Encompass Health from $150.00 to $155.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Sunday, August 16th. Barclays upped their price target on shares of Encompass Health from $140.00 to $144.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Weiss Ratings raised shares of Encompass Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $148.71.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.